Artificial Intelligence

A new partnership between Takara Bio and Hamilton promises to revolutionize RNA-seq, making high-throughput genomic analysis faster and more reliable.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new partnership aims to merge digital brain therapies with functional foods, targeting Japan and Southeast Asia's rapidly growing elderly populations.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.

Constellis hires Joseph Zobro as Chief Legal Officer, signaling a strategic pivot towards agile procurement and integrating AI into its global security operations.

With $8M in funding, Huskeys' new AI platform sits on top of existing firewalls, promising to stop blocking customers and start generating revenue.

In an AI-obsessed world, strategic advisory firm Hakluyt bets on people, posting massive profit growth and adding tech titans to its elite board.

A new company, PrimeTech, is launching with AI-driven design and a decentralized factory model to tackle labor shortages and build homes faster.

After a transformative year with key FDA/EU approvals, Pulsenmore's financials get a one-time boost. Can it now conquer the remote prenatal care market?

Japanese pharma giant Meiji Seika Pharma backs Centivax's quest for a universal flu vaccine, a move that could revolutionize global pandemic preparedness.

Xplor Technologies and Clubessential merge, forming a $900M global leader with a new CEO and a bold eight-figure investment in artificial intelligence.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

A Georgia firm's painless patch technology earns top honors, promising to revolutionize medicine delivery and solve critical global health challenges.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Kekst CNC appoints 20-year veteran Lyndsey Estin as Co-CEO, signaling a strategic focus on AI and cybersecurity in a major leadership shift.

Following rapid growth and a private equity acquisition, DAS Health appoints Lee Horner to navigate healthcare's complex digital and cybersecurity challenges.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.